<DOC>
	<DOCNO>NCT00377741</DOCNO>
	<brief_summary>This study assess relative bioavailability ganciclovir pro-drug valganciclovir lung transplant recipient without cystic fibrosis . Each patient receive 900mg valganciclovir daily period specify center , start soon possible transplant . Pharmacokinetic assessment make provide steady-state kinetics ganciclovir immunosuppressive drug obtain ( &gt; =4 day drug therapy ) . Blood sample pharmacokinetic analysis take 24h post-dose one occasion . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Relative Bioavailability Study Valcyte ( Valganciclovir ) Lung Transplant Recipients With Without Cystic Fibrosis .</brief_title>
	<detailed_description />
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>male female patient , &gt; =14 year age ; first lung heartlung transplant recipient ; risk CMV disease ( D+R , D+R+ DR+ ) ; estimate creatinine clearance &gt; =60mL/min ; stable immunosuppressive 900mg Valcyte dosing regimen ( &gt; =4 day ) prior pharmacokinetic assessment . history adverse reaction acyclovir , valacyclovir , ganciclovir valganciclovir ; evidence graft rejection ; patient receive antiCMV prophylaxis treatment cytogam , ganciclovir valganciclovir transplant screening .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>